<DOC>
	<DOC>NCT01931189</DOC>
	<brief_summary>The purpose of this study is to assess equivalence of pharmacokinetics between NI-071 and infliximab(the comparator) in Japanese healthy volunteers</brief_summary>
	<brief_title>Pharmacokinetics Study of NI-071</brief_title>
	<detailed_description />
	<mesh_term>Infliximab</mesh_term>
	<criteria>1. Healthy male subjects (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, clinical laboratory tests, etc.) 2. Body Mass Index (BMI) of 18.5 to 25.0 kg/m2, and a total body weight of 50 to 80 kg 1. Subjects with a following past History or concomitant diseases Chronic or recurrent infectious disease Demyelinating disease Congestive heart failure lymphoproliferative disorder or myelodysplastic syndrome Malignancy Interstitial lung disease 2. Subjects with active or latent tuberculosis or history of tuberculosis</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>